Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $13.22 in the prior trading day, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $13.16, down -0.45%. In other words, the price has decreased by -$0.45 from its previous closing price. On the day, 0.73 million shares were traded. DAWN stock price reached its highest trading level at $13.39 during the session, while it also had its lowest trading level at $13.01.
Ratios:
Our goal is to gain a better understanding of DAWN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.55 and its Current Ratio is at 14.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’24 when Bender Jeremy sold 10,554 shares for $13.21 per share. The transaction valued at 139,420 led to the insider holds 108,377 shares of the business.
Blackman Samuel C. sold 2,206 shares of DAWN for $29,142 on Nov 18 ’24. The HEAD OF R&D now owns 1,064,015 shares after completing the transaction at $13.21 per share. On Nov 18 ’24, another insider, Dubow Adam, who serves as the GENERAL COUNSEL of the company, sold 3,165 shares for $13.21 each. As a result, the insider received 41,810 and left with 32,162 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1327133312 and an Enterprise Value of 771369216. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.02 while its Price-to-Book (P/B) ratio in mrq is 2.39. Its current Enterprise Value per Revenue stands at 7.566 whereas that against EBITDA is -3.754.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $11.51. The 50-Day Moving Average of the stock is -7.53%, while the 200-Day Moving Average is calculated to be -9.28%.
Shares Statistics:
The stock has traded on average 1.10M shares per day over the past 3-months and 981840 shares per day over the last 10 days, according to various share statistics. A total of 100.81M shares are outstanding, with a floating share count of 72.61M. Insiders hold about 28.00% of the company’s shares, while institutions hold 81.48% stake in the company. Shares short for DAWN as of 1732838400 were 19486769 with a Short Ratio of 17.76, compared to 1730332800 on 18018911. Therefore, it implies a Short% of Shares Outstanding of 19486769 and a Short% of Float of 23.34.
